This study shows for the first time that microbial metabolites like Queuosine contribute to therapy resistance in pancreatic cancer under conditions of obesity by upregulating PRDX1, which protects them from chemotherapy induced oxidative stress. Here, PRDX1 is linked to obesity due to melanocortin 4 receptor deficiency.